Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Nesbuvir

Known as: 5-Cyclopropyl-2-(4-fluorophenyl)-6-((2-hydroxyethyl)(methylsulfonyl)amino)-N-methyl-1-benzofuran-3-carboxamide 
A non-nuceoside polymerase inhibitor with activity against hepatitis C virus (HCV). Nesbuvir binds to the palm site II pocket of HCV NS5B polymerase… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
This letter describes the discovery of a fused benzofuran scaffold viable for preparing a series of novel potent HCV NS5B… Expand
2018
2018
With the introduction of direct-acting antivirals (DAAs), treatment against hepatitis C virus (HCV) has significantly improved… Expand
2017
2017
Significance Introduction of new anti-hepatitis C virus (HCV) agents, so-called direct-acting antivirals (DAAs), has greatly… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2017
2017
Allosteric inhibitors of hepatitis C virus (HCV) non-structural protein 5B (NS5B) polymerase are effective for treatment of… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
2017
2017
&NA; The development of direct‐acting antivirals (DAAs) has significantly improved hepatitis C virus (HCV) treatment. However… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
2015
2015
Hepatitis C virus, an enveloped positive – stranded RNA virus and the sole member of the genus Hepacivirus within the… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 3
  • table 2
2014
2014
ABSTRACT Direct-acting antivirals (DAAs) targeting proteins encoded by the hepatitis C virus (HCV) genome have great potential… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2